Pharmaceutical

Image

Global Focal Segmental Glomerulosclerosis Market – Industry Trends and Forecast to 2031

  • Pharmaceutical
  • Upcoming Report
  • Feb 2024
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Focal Segmental Glomerulosclerosis Market, By Type (Primary, Secondary), Treatment (Drug Therapy, Dialysis, Kidney Transplant, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2031.

Focal Segmental Glomerulosclerosis Market

Focal Segmental Glomerulosclerosis Market Analysis and Size

The focal segmental glomerulosclerosis market is expected to witness significant growth during the forecast period. The occurrence of focal segmental glomerulosclerosis is comparatively high when compared to other glomerular diseases. Presently, there are no FDA-approved therapies for focal segmental glomerulosclerosis. The therapeutic market size of focal segmental glomerulosclerosis in the U.S. mostly accounted for the off-label treatment options, such as non-immune therapy in combination with immunotherapy.

Data Bridge Market Research analyzes that the global focal segmental glomerulosclerosis market, which was USD 24.01 billion in 2023, would rocket up to 47.50 billion by 2031 and is expected to undergo a CAGR of 8.9% during the forecast period. “Hospitals" dominate the end-user segment of the market due to increasing awareness of proper treatment. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Focal Segmental Glomerulosclerosis Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2031

Base Year

2023

Historic Years

2022 (Customizable to 2016-2021)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

By Type (Primary, Secondary), Treatment (Drug Therapy, Dialysis, Kidney Transplant, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of the Middle East & Africa

Market Players Covered


Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.) GSK Plc. (U.K.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Accord Healthcare (U.K.), Wockhardt (India)

Market Opportunities

  • Growing elderly population
  • Increased R&D activities

Market Definition

Focal segmental glomerulosclerosis is a type of renal disorder affecting the small filtering unit of kidneys called glomeruli which involves scarring of kidney. It is caused by numerous factors such as autoimmune disorders, genetic factors, and infection in other parts of the body and sclerotic diseases. It is one of the rare diseases that affects kidney function by damaging and attacking the glomeruli. Kidney defects typically characterize this disease by obesity, sickle cell anemia, obstructive sleep apnea, birth, and viruses such as HIV.

Global Focal Segmental Glomerulosclerosis Market Dynamics

Drivers

  • Increased Prevalence of Focal Segmental Glomerulosclerosis

Focal segmental glomerulosclerosis (FSGS) is a rare health condition affecting about 210,200 patients globally and around 14,000 to 16,000 new cases are diagnosed annually. The increasing numbers along the considerable opportunities are boosting the growth of the market.

  • Higher Therapeutic Options

The latest therapy for the primary FSGS includes immunosuppressive agents, such as glucocorticoids and calcineurin inhibitors. Additionally, steroid therapy is among the most basic and standard treatment with oral prednisone. Some of the main evolving companies having their potential drug candidates in the pipeline are Chemocentryx, Pharmaceuticals, Retrophin Inc., Reata, and Vertex Pharmaceuticals. This boosts the market growth.

Opportunities

  • Growing Elderly Population

Life expectancy is increasing all over the globe, which has led to an upsurge in the elderly population. This trend positively impacts the industry by increasing the disease occurrence and creating per capita demand for its remedies. A rise in elderly visits to outpatient facilities and ambulatory surgery centers (ASC) results in the sound growth of the focal segmental glomerulosclerosis market during the forecast period. Thus, it creates more opportunities for the market growth.

  • Increased Diagnostic Tests

Several advances in pathogenesis of focal segmental glomerular sclerosis (FSGS) resulted in the market for research in the focal segmental glomerular sclerosis (FSGS). Several etiologies drive focal segmental glomerulosclerosis (FSGS). Rising awareness about occurrence of kidney disease drive prospects in the FSGS market. Given the increased mortality in patient populations, important advances were made in genetic testing, lab testing, and kidney biopsies. These new treatment methods are creating more opportunities for the market.

 Restraints/Challenges

  • Lack of Medical Care

The lack of medical care in undeveloped economies may restrain the growth of focal segmental glomerulosclerosis market during the forecast period. Not much awareness leads to the unavailability of treatment and limits market growth.

  • High Cost

The huge expenditure associated with drug therapy, dialysis, kidney transplant hamper the market growth. The huge drug development and associated processes hamper the market's growth.

Global Focal Segmental Glomerulosclerosis Market Scope

The focal segmental glomerulosclerosis market is segmented on the basis of type, treatment, route of administration, end-user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Primary
  • Secondary

Treatment

  • Drug Therapy
  • Dialysis
  • Kidney Transplant
  • Others

Route of Administration

  • Oral
  • Parenteral

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Global Focal Segmental Glomerulosclerosis Market Regional Analysis/Insights

The focal segmental glomerulosclerosis market is analyzed and market size insights and trends are provided by country type, treatment, route of administration, end-user, and distribution channel as referenced above.

The countries covered in the market report are the U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Russia, Poland, Switzerland, Netherlands, Hungary, Austria, Norway, Ireland, Turkey, Lithuania, rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Kuwait, Egypt, and rest of Middle East & Africa.

North America is expected to dominate the market due to the high diagnostic rate and presence of key players in this region.

Asia-Pacific is expected to show significant growth in the market throughout the forecasted period due to the growing cases of kidney disorder, the presence of sophisticated medical facilities to maximize the treatment effectiveness for a patient suffering from glomerular disease, and increased focus on research and development activity.

The country section of the report also provides individual market-impacting factors and domestic regulation changes that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

The focal segmental glomerulosclerosis market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for focal segmental glomerulosclerosis market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on focal segmental glomerulosclerosis market. The data is available for historic period 2010-2020.

Competitive Landscape and Global Focal Segmental Glomerulosclerosis Market Share Analysis

The focal segmental glomerulosclerosis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to focal segmental glomerulosclerosis market.

Some of the major players operating in the focal segmental glomerulosclerosis market are:

  • Pfizer Inc (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Mylan N.V. (U.S.)
  • Fresenius Kabi AG (Germany)
  • Hikma Pharmaceuticals PLC (U.K.)
  • Novartis AG (Switzerland)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Bristol Myers Squibb Company (U.S.)
  • GSK Plc. (U.K.)
  • Bayer AG (Germany)
  • Sun Pharmaceutical Industries Ltd (India)
  • Accord Healthcare (U.K.)
  • Wockhardt (India)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The Focal Segmental Glomerulosclerosis Market size will be worth USD 47.50 billion by 2031 during the forecast period.
The Focal Segmental Glomerulosclerosis Market growth rate is 8.9% during the forecast period.
The Increased Prevalence of Focal Segmental Glomerulosclerosis and Higher Therapeutic Options are the growth drivers of the Focal Segmental Glomerulosclerosis Market.
The type, treatment, route of administration, end-user, and distribution channel are the factors on which the Focal Segmental Glomerulosclerosis Market research is based.
The major companies in the Focal Segmental Glomerulosclerosis Market are Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.) GSK Plc. (U.K.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Accord Healthcare (U.K.), Wockhardt (India).
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials